110506-42-8

Basic information

• Product Name: 2-(4-aminophenoxy)-1-(4-methylpiperazin-1-yl)ethan-1-one
• Synonyms: 2-(4-aminophenoxy)-1-(4-methylpiperazin-1-yl)ethan-1-one;2-(4-aminophenoxy)-1-(4-methylpiperazin-1-yl)ethanone
• CAS NO: 110506-42-8
• Molecular Formula: C₁₃H₁₉N₃O₂
• Molecular Weight: 249.30886
• Mol File: 110506-42-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-aminophenoxy)-1-(4-methylpiperazin-1-yl)ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-aminophenoxy)-1-(4-methylpiperazin-1-yl)ethan-1-one(110506-42-8)
• EPA Substance Registry System: 2-(4-aminophenoxy)-1-(4-methylpiperazin-1-yl)ethan-1-one(110506-42-8)

Safety Data

• Hazardous Substances Data: 110506-42-8(Hazardous Substances Data)

Upstream product

• 110506-23-5 1-methyl-4-<(4-nitrophenoxy)acetyl>piperazine 
• 109-01-3 1-methyl-piperazine 
• 20142-88-5 2-(4-nitrophenoxy)acetyl chloride 
• 112257-15-5 2-bromo-1-(4-methylpiperazin-1-yl)ethan-1-one 
• 123-30-8 4-amino-phenol 
• 1798-11-4 4-nitrophenoxyacetic acid 

Downstream Products

• 110506-68-8 2-(4-Isothiocyanato-phenoxy)-1-(4-methyl-piperazin-1-yl)-ethanone 

Relevant articles and documents

(E)-3-(Aryl(arylamino)methylene)indolin-2-one derivatives: An efficient synthetic approach and evaluation of their cancer inhibitory activity

A series of (E)-3-(aryl(arylamino)methylene)indolin-2-one derivatives were synthesised using an efficient synthetic approach. The method involved reaction of 3-bromo-3-(bromo(aryl)methyl)indolin-2-one with substituted anilines through nucleophilic substitution and a simultaneous elimination using NaHCO3 in DMF. The anticancer activity of the products against four cell lines, HCT-116, A549, SKOV3 and MDA-MB-231, was also evaluated, and several compounds showed moderate inhibitory activity.

Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors

The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders.Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy.Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release.These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines.After examining a large number of analogs, N--4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.

4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines

This disclosure describes novel 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines having anti-asthmatic activity.

Synthesis of Some New 3-Methoxy-4-acylaminophenylisothiocyanates, 4'-Isothiocyanatophenoxyacetamides/Isobutyramides as Possible Anthelmintic Agents

A number of new 3-methoxy-4-acylaminophenylisothiocyanates (II and III), 4'-isothiocyanatophenoxyacetamides (IV) and 4-isothiocyanatophenoxyisobutyramides (V) have been synthesized and tested for anthelmintic, antiamoebic and antitrichomonal activities.